Teva Pharmaceutical

🚨 Reasons for Boycotting Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is an israel-based multinational pharmaceutical company incorporated in israel on February 13, 1944, headquartered in Tel Aviv, israel, and traded on the New York Stock Exchange and the Tel Aviv Stock Exchange. The company owns products including Copaxone, Ajovy, Austedo, Uzedy, Simlandi, and a generic drug portfolio. Teva is israel's largest pharmaceutical company and operates manufacturing, R&D, and headquarters facilities in israel. By refusing to sever ties with israel and paying hundreds of millions of dollars to the israeli tax authority, it contributes to the normalization of genocide.

1. israel's Largest Pharmaceutical Company and Headquarters in israel: Teva was incorporated in israel on February 13, 1944 and is israel's largest pharmaceutical company. Its headquarters are at 124 Dvora HaNevi'a St., Tel Aviv, israel. The company has manufacturing and R&D facilities in israel. Teva employs approximately 37,000 people across 57 markets worldwide. The company's operations in israel have "remain largely unaffected" by the war ongoing since October 2023. This demonstrates that Teva provides uninterrupted support to israel's war machine.SEC Filing: Teva — We operate worldwide, with headquarters in israel — 37,000 employees — operations in israel remain largely unaffected (2025)SEC Filing: Teva was incorporated in israel on February 13, 1944SEC Filing: 124 Dvora HaNevi'a St., Tel Aviv, israel
   
   Employment and Operations in israel: Teva has 650 israel-based employees in its TAPI (Active Pharmaceutical Ingredients) division. The company announced plans in June 2026 to lay off 250 employees in this unit. Teva's Teva Tech facility in israel is located in Ramat Hovav (southern israel).Haaretz: israeli Pharma Giant Teva Lays Off 250 of Its israel-based Staff — TAPI division has 650 israel-based employees (June 2026)Ynetnews: Teva to cut 250 jobs at israel plant — Teva Tech plant in Ramat Hovav (June 2026)
2. $750 Million Agreement with the israel Tax Authority: In June 2024, Teva reached an agreement with the israel Tax Authority (ITA) to settle all pending litigation for the tax years 2008-2020. Under the agreement, Teva will pay a total of $750 million in installments between 2024 and 2029. In 2025, the current tax expense in israel was recorded as $154 million. These payments demonstrate that Teva directly contributes financially to the israeli regime and its military.Nasdaq: Teva Reaches Agreement With the israel Tax Authority — Company will pay a total of $750 million in installments between 2024 to 2029 (June 2024)SEC Filing: Income Taxes — Schedule of the Provision for Income Taxes — israel (domestic) Current $154 million (2025)SEC Filing: The statutory israeli corporate tax rate is 23% in 2025 — Teva entered into an agreement with the israeli Tax Authorities
3. Lawsuit Against Boycott Campaigners in France: In France, Teva filed a "defamation" lawsuit against Olivia Zemor, editor of the EuroPalestine website. Zemor was tried in 2016 for calling for a boycott of Teva. Zemor stated that Teva, "through its financial contribution to israel, contributes to the financing of military operations in Gaza and to the development of colonization in the West Bank and East Jerusalem." Teva's lawyer claimed that the company "is not involved in a geopolitical, ethnic, or religious conflict." In September 2026, the French Court of Cassation overturned the anti-boycott ruling. This case demonstrates that Teva attempts to silence boycott campaigns through legal means.RadioHC: Pro-Palestine activist stands trial after leading boycott action — Teva provides millions in tax revenue to the israeli regime and its military (March 2026)EuroPalestine: Boycott — victory against the genocidal at the Court of Cassation (September 2026)The New Arab: French BDS activist stands trial over calls for israeli boycott (March 2021)
4. Institutional Shareholders: BlackRock and Vanguard: According to Investing.com and ADVFN data, BlackRock, Inc. holds 5.97% (69,525,534 shares) and Vanguard Capital Management, LLC holds 3.66% (42,593,636 shares) of Teva. BlackRock and Vanguard are identified in a UN report (OHCHR) as being among the largest investors in companies pivotal to israel's weapons arsenal. This means that profits generated by Teva partly flow to these funds, indirectly contributing to israel's weapons industry.Investing.com: BlackRock, Inc. — 5.97% (69,525,534 shares) — Vanguard Capital Management, LLC — 3.66% (42,593,636 shares) — Teva Pharmaceutical Industries Ltd (TEVA) OwnershipADVFN: BlackRock 5.97%, Vanguard 3.67% — Teva Pharmaceutical Industries Ltd (TEVA) Ownership DistributionUN OHCHR: Report of the Special Rapporteur Francesca Albanese (2025)
5. Double Standards and Silence: Teva emphasizes its commitments to corporate responsibility and ethical principles. However, the company continues to operate its headquarters and manufacturing facilities in israel, pays hundreds of millions of dollars to the israeli tax authority, and has issued no statement condemning the genocide in Gaza or the illegal settlement enterprise in the West Bank. This contradiction between corporate responsibility claims and actual corporate cooperation with israel exposes the company's double standards.Teva Pharmaceutical Industries: Corporate Responsibility

🌐 Sources

• SEC Filing: Teva — headquarters in israel, 37,000 employees, operations largely unaffected (2025)
• Nasdaq: Teva Reaches Agreement With israel Tax Authority — $750 million (June 2024)
• SEC Filing: Income Taxes — israel (domestic) Current $154 million (2025)
• RadioHC: Pro-Palestine activist stands trial after leading boycott action (March 2026)
• Investing.com: Teva Ownership — BlackRock 5.97%, Vanguard 3.66%
• Haaretz: Teva lays off 250 israel-based staff (June 2026)
• UN OHCHR: Report of the Special Rapporteur Francesca Albanese (2025)

Boykot Market has listed the brand information and source links above based on verifiable official sources. Please conduct your own research to be certain.